CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 3
Pages: 1  2  
Next
 

Pathogenesis of AIDS-Related Kaposi's Sarcoma

By

Christos Emmanoulides, MD, Steven A. Miles, MD, and Ronald T. Mitsuyasu, MD


Division of Hematology-Oncology, and Department of Medicine, University of California, Los Angeles | March 1, 1996

The occurrence of Kaposi's sarcoma (KS) in patients with HIV infection is more than 7,000 times higher than in the non-HIV infected population. The reason for this association is unclear but may involve decreased immune surveillance as a result of the profound cellular immune deficiency caused by HIV, a sexually transmitted KS-inducing virus, whose KS-transforming capabilities may be enhanced by HIV, or a direct or indirect effect of HIV itself in susceptible individuals. Over the last few years, advances have been made in our understanding of the pathogenesis of this tumor, and several models have been proposed for its development in the setting of AIDS. Better characterization of the processes involved in the development of KS will ultimately lead to more effective methods of treating and preventing this unusual tumor. [ONCOLOGY 10(3):335-350, 1996]

Introduction

Kaposi's sarcoma (KS) was first described in 1872 as a rare vascular tumor characterized by multiple skin nodules of the lower extremity, which was seen primarily in older men of eastern European or Mediterranean descent [1]. The tumor rarely involved visceral organs and generally had an indolent course. A more virulent, endemic form of KS was subsequently described in sub-Saharan Africa and involved younger men with cutaneous, lymphatic, and visceral involvement. It ran a more aggressive clinical course. Yet another group of non-HIV-infected patients with KS were those who received immunosuppressive therapy for organ transplantation or an autoimmune disease and in whom occasional spontaneous regression of lesions had been reported with withdrawal of immunosuppressive therapy. These various KS-affected populations suggested possible genetic, infectious, and immunologic underpinnings to the development of these tumors [2].

AIDS-Related KS

The recognition of KS in US male homosexuals in the early 1980s heralded the AIDS epidemic [3]. Early descriptions of AIDS suggested that as many as 50% of gay men with T-cell immune deficiency developed KS as one of their manifestations of AIDS. The proportion of patients with KS as the initial manifestation of AIDS has declined to approximately 11% in 1991 [4,5]. Several characteristics of this tumor, including its more aggressive clinical course; frequent involvement of lymph nodes, gastrointestinal tract, lung, and other viscera; and its almost exclusive early occurrence in the gay male AIDS population with other evidence of immune deficiency suggested that this tumor was more akin to the African variant of KS and likely was associated with a sexually transmitted agent.

An additional feature of AIDS-related KS (AIDS/KS) that must be explained in any model of pathogenesis includes the fact that approximately 90% of AIDS/KS cases in the United States occur in homosexual men, and far fewer cases have been seen in women, intravenous drug users, or heterosexual males. Kaposi's sarcoma has also been described in homosexual males who are not HIV-infected [6]. While the number of HIV-infected women is lower than the number of men, the frequency of KS in women is relatively high in Africa and in women in western countries who have had sex with bisexual men, compared to those whose sexual partners are heterosexuals or intravenous drug users (3% vs 0.7%) [7].

These findings suggest that a sexually transmitted infectious agent likely is involved in the pathogenesis of KS and that this agent is more prevalent in US gay men and the general African population. The findings also suggest that androgens or other male factors may facilitate the development of this tumor.

Viral Etiology

The declining incidence of KS in the gay male population in the mid- to late 1980s as a result of increased awareness of HIV and the more widespread use of safe sex practices led to speculation that sexually transmitted infections may be associated with the development of this tumor. Declining incidence of cytomegalovirus (CMV) seropositivity in association with declining occurrence of KS led to speculation of a potential role for this virus in KS pathogenesis [8,9]. Cytomegalovirus was not consistently detected by in situ hybridization or other methods in KS tissue, however, and the widespread prevalence of this virus in AIDS patients who do not have KS argue against the involvement of CMV in KS tumor development [10].

There also has been speculation about the potential role that other DNA viruses, such as an Epstein Barr-like virus (EBV) [11] and the human papilloma virus (HPV), may play in the pathogenesis of KS [12]. However, the fact these viral sequences have not uniformly been found in KS tumors suggests that infection with these viruses may be more coincidental than causative for KS. No clear evidence of the involvement of CMV, EBV, or HPV in the development of KS has yet been established.

KS-Associated Herpesvirus

Recently, using representational difference analyses, Chang and Moore have identified sequences of a unique gamma human herpesvirus, termed the KS-associated herpesvirus (KSHV), in high frequency in KS tissues from patients with AIDS [13]. These viral sequences, somewhat homologous to sequences of the herpes saimiri virus, which can induce lymphoma in monkeys, have been identified in more than 90% of KS biopsies from HIV-infected and uninfected individuals but not in uninvolved tissues from the same patients or from normal controls [14-16].

Sequences of KSHV also have been found in an unusual variant of non-Hodgkin's lymphoma in patients with AIDS (ie, body cavity lymphomas), in association with EBV [17]. However, the recent finding of KSHV-like sequences in patients with other dermatologic disorders and the loss of these particles in multiple passaged KS cell lines raises the possibility that this virus could be a passenger virus rather than a directly transforming one [18]. Determination of the exact role of KSHV in the pathogenesis of KS will require viral isolation and further characterization of the direct and indirect effects of this virus. However, detection of KSHV sequences in high frequency and specificity in patients with KS has led to renewed interest in the role of viruses in the development of tumors in the setting of immunosuppression and in the possible use of viral inhibitory agents in controlling tumor development and growth.

Pathology

Lesions of KS vary considerably in their clinical presentation and, to a lesser degree, in their histologic appearance. These lesions can involve predominantly the skin and oral mucosa, as well as a number of visceral organs, and can range in appearance from pink or red macules to dark blue and purple papules or nodules.

Histologically, KS lesions are characterized by intense neovascularization and the appearance of spindle cells, which are considered to be the tumor cells of KS. The spindle cells proliferate among characteristic slit-like spaces produced by the aberrant vascular structures. These cells have a low mitotic index and are euploid [19,20]. Fibroblasts, extravasated red blood cells, and inflammatory cells are mixed in with the spindle cells. The histologic characteristics of early and advanced KS differ in that the spindle cells in advanced lesions are more abundant and form more compact masses.

The origin of the spindle cells is somewhat controversial, as these cells share several histologic features with various other types of cells [21]. Immunohistochemically, spindle cells are somewhat similar to endothelial cells in that they stain with Ulex europaeus and are negative to factor VIII(Drug information on factor viii) and EN-4 [22]. A mesenchymal origin is suggested by the presence of alpha-actin, a smooth muscle marker, and shared positivity with the hematopoietic cell markers CD34 and CD18 [23]. It is currently believed that KS most likely is of mesenchymal origin, possibly a smooth muscle progenitor, with multiphenotypic markings reflective of early differentiation or transformation.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
  • Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
  • Obesity Impairs Efficacy of L-Asparaginase in Leukemia Treatment
  • New AUA Guidelines for Prostate Cancer Screening
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy